Premium
Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676)
Author(s) -
De Vetten M. P.,
Jansen J. H.,
Van Der Reijden B. A.,
Berger M. S.,
Zijlmans J. M. J. M.,
Löwenberg B.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2000.02402.x
Subject(s) - gemtuzumab ozogamicin , calicheamicin , cd33 , medicine , conjugate , myeloid leukemia , cd34 , stem cell , biology , mathematical analysis , genetics , mathematics
The anti‐CD33 monoclonal antibody linked to NAc‐gamma calicheamicin gemtuzumab ozogamicin (CMA‐676) was used to treat a patient with Philadelphia/bcr‐abl‐positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real‐time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3‐log tumour mass reduction in bone marrow.